Comparative Pharmacology
Head-to-head clinical analysis: RENFLEXIS versus SIMPONI ARIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENFLEXIS versus SIMPONI ARIA.
RENFLEXIS vs SIMPONI ARIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Renflexis (infliximab-abda) is a chimeric monoclonal antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory activity. It inhibits TNFα binding to its receptors (TNFR1 and TNFR2), reducing inflammatory cell migration, cytokine production, and tissue damage.
Golimumab is a human IgG1κ monoclonal antibody that binds to and neutralizes tumor necrosis factor alpha (TNF-α), preventing its interaction with p55 and p75 cell surface TNF receptors. This reduces pro-inflammatory cytokine production and immune cell activation.
5 mg/kg intravenously over at least 2 hours at 0, 2, and 6 weeks, then every 8 weeks.
2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter.
None Documented
None Documented
Terminal elimination half-life approximately 18-21 days (mean ~20 days) in patients with rheumatoid arthritis; supports every-8-week dosing interval.
Terminal elimination half-life approximately 10-13 days (mean 12 days), allowing for every 2-week dosing after initial loading regimen.
Primarily eliminated via reticuloendothelial system degradation; renal excretion accounts for <1% of dose as unchanged drug; no significant biliary or fecal excretion.
Primarily degraded into small peptides and amino acids via reticuloendothelial system; negligible renal (0.1%) and fecal (<1%) excretion; no significant biliary elimination.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor